北美视神经脊髓炎谱系疾病和髓鞘少突胶质细胞糖蛋白抗体疾病患者的 COVID-19：来自 COViMS 登记处。
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry.
机构信息
From the Johns Hopkins University School of Medicine (S.D.N.), Baltimore, MD; Washington University in St. Louis School of Medicine (A.H.C., A.S.), MO; Mellen Center for MS (R.J.F.), Cleveland Clinic, OH; Consortium of MS Centers (J.H.), Hackensack, NJ; MS Society of Canada (P.K.), Toronto, Ontario, Canada; National Multiple Sclerosis Society (B.B.) New York, NY; University of British Columbia (D.L.), Vancouver, British Columbia, Canada; The University of Alabama at Birmingham (G.R.C.); and University of Miami School of Medicine (K.W.R.), FL.
出版信息
Neurol Neuroimmunol Neuroinflamm. 2021 Aug 24;8(5). doi: 10.1212/NXI.0000000000001057. Print 2021 Sep.
BACKGROUND AND OBJECTIVE
To describe the impact of coronavirus disease 2019 (COVID-19) on people with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD).
METHODS
The COVID-19 Infections in Multiple Sclerosis (MS) and Related Diseases (COViMS) Registry collected data on North American patients with MS and related diseases with laboratory-positive or highly suspected SARS-CoV-2 infection. Deidentified data were entered into a web-based registry by health care providers. Data were analyzed using -tests, Pearson χ tests, or Fisher exact tests for categorical variables. Univariate logistic regression models examined effects of risk factors and COVID-19 clinical severity.
RESULTS
As of June 7, 2021, 77 patients with NMOSD and 20 patients with MOGAD were reported in the COViMS Registry. Most patients with NMOSD were laboratory positive for SARS-CoV-2 and taking rituximab at the time of COVID-19 diagnosis. Most patients with NMOSD were not hospitalized (64.9% [95% CI: 53.2%-75.5%]), whereas 15.6% (95% CI: 8.3%-25.6%) were hospitalized only, 9.1% (95% CI: 3.7%-17.8%) were admitted to the ICU and/or ventilated, and 10.4% (95% CI: 4.6%-19.5%) died. In patients with NMOSD, having a comorbidity was the sole factor identified for poorer COVID-19 outcome (OR = 6.0, 95% CI: 1.79-19.98). Most patients with MOGAD were laboratory positive for SARS-CoV-2, and almost half were taking rituximab. Among patients with MOGAD, 75.0% were not hospitalized, and no deaths were recorded; no factors were different between those not hospitalized and those hospitalized, admitted to the ICU, or ventilated.
DISCUSSION
Among the reported patients with NMOSD, a high mortality rate was observed, and the presence of comorbid conditions was associated with worse COVID-19 outcome. There were no deaths reported in the patients with MOGAD, although these observations are limited due to small sample size.
背景与目的
描述 2019 年冠状病毒病（COVID-19）对视神经脊髓炎谱系疾病（NMOSD）和髓鞘少突胶质细胞糖蛋白抗体疾病（MOGAD）患者的影响。
方法
COVID-19 感染多发性硬化症（MS）及相关疾病（COViMS）登记处收集了北美 MS 和相关疾病患者的实验室阳性或高度疑似 SARS-CoV-2 感染的数据。医疗保健提供者通过网络注册将匿名数据输入。使用检验、Pearson χ 检验或 Fisher 精确检验对分类变量进行分析。单变量逻辑回归模型研究了危险因素和 COVID-19 临床严重程度的影响。
结果
截至 2021 年 6 月 7 日，COViMS 登记处报告了 77 例 NMOSD 患者和 20 例 MOGAD 患者。大多数 NMOSD 患者的 SARS-CoV-2 实验室检测呈阳性，且在 COVID-19 诊断时正在接受利妥昔单抗治疗。大多数 NMOSD 患者未住院（64.9%[95%CI：53.2%-75.5%]），而 15.6%（95%CI：8.3%-25.6%）仅住院，9.1%（95%CI：3.7%-17.8%）入住 ICU 并/或需要通气，10.4%（95%CI：4.6%-19.5%）死亡。在 NMOSD 患者中，合并症是 COVID-19 预后不良的唯一因素（OR=6.0，95%CI：1.79-19.98）。大多数 MOGAD 患者的 SARS-CoV-2 实验室检测呈阳性，近一半正在接受利妥昔单抗治疗。MOGAD 患者中，75.0%未住院，无死亡记录；未住院与住院、入住 ICU 或通气的患者之间无差异。
讨论
在报告的 NMOSD 患者中，死亡率较高，且合并症与 COVID-19 预后不良相关。MOGAD 患者无死亡报告，但由于样本量小，这些观察结果受到限制。
Zotero 插件